文献速递MDS 与骨髓增殖性肿瘤

骨髓纤维化的靶向治疗:现状、进行中的研究与未来展望

Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives.
PubMed 文献 · Am J Hematol · 2025-03-10

骨髓纤维化(MF)超过90%病例伴JAK2、CALR或MPL驱动突变,导致JAK-STAT通路持续激活。芦可替尼为同类首个JAK1/JAK2抑制剂,后续非德拉替尼、帕克替尼、莫美洛替尼获批;莫美洛替尼通过抑制ACVR1降低hepcidin而改善贫血。现有JAK抑制剂主要抗炎,对生存或疾病进展影响有限,本文综述已获批及在研靶向治疗及其生物学背景。

要点

  • MF超过90%病例携带JAK2、CALR或MPL驱动突变,导致JAK-STAT通路持续激活。
  • 芦可替尼为同类首个JAK1/JAK2抑制剂,非德拉替尼、帕克替尼、莫美洛替尼后续获批。
  • 莫美洛替尼通过抑制ACVR1降低hepcidin表达而改善贫血,并缩小脾脏、减轻症状。

核心结论

  • 现有JAK抑制剂表现似抗炎药,对生存或疾病进展无重大影响。
  • 选择性JAK2 V617F抑制剂及针对突变CALR的免疫治疗是最引人关注且有前景的方法。

研究设计与样本

  • 本文为综述,聚焦MF已获批及实验性治疗并突出其生物学背景。

主要发现

  • MF为骨髓增殖性肿瘤,超过90%病例伴JAK2、CALR或MPL驱动突变,导致JAK-STAT通路持续激活。
  • MF特征包括三系髓系增殖伴显著巨核细胞异型及骨髓纤维化、脾肿大、全身症状、无效造血、髓外造血、白血病转化风险及生存期缩短。
  • 治疗可从低危无症状患者单纯观察至异基因造血干细胞移植,后者为唯一可能治愈并延长生存的治疗,但伴显著发病率和死亡率。
  • JAK2 V617F突变的发现促成JAK抑制剂开发,包括同类首个JAK1/JAK2抑制剂芦可替尼及后续获批的非德拉替尼、帕克替尼、莫美洛替尼。
  • 莫美洛替尼通过抑制ACVR1降低hepcidin表达而显示红细胞生成获益,并缩小脾肿大和减轻症状。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myelofibrosis (MF) is a myeloproliferative neoplasm that is accompanied by driver JAK2, CALR, or MPL mutations in more than 90% of cases, leading to constitutive activation of the JAK-STAT pathway. MF is a multifaceted disease characterized by trilineage myeloid proliferation with prominent megakaryocyte atypia and bone marrow fibrosis, as well as splenomegaly, constitutional symptoms, ineffective erythropoiesis, extramedullary hematopoiesis, and a risk of leukemic progression and shortened survival. Therapy can range from observation alone in lower-risk and asymptomatic patients to allogeneic hematopoietic stem cell transplantation, which is the only potentially curative treatment capable of prolonging survival, although burdened by significant morbidity and mortality. The discovery of the JAK2 V617F mutation prompted the development of JAK inhibitors (JAKi) including the first-in-class JAK1/JAK2 inhibitor ruxolitinib and subsequent approval of fedratinib, pacritinib, and momelotinib. The latter has shown erythropoietic benefits by suppressing hepcidin expression via activin A receptor type 1 (ACVR1) inhibition, as well as reducing splenomegaly and symptoms. However, the current JAKi behave as anti-inflammatory drugs without a major impact on survival or disease progression. A better understanding of the genetics, mechanisms of fibrosis, cytopenia, and the role of inflammatory cytokines has led to the development of numerous therapeutic agents that target epigenetic regulation, signaling, telomerase, cell cycle, and apoptosis, nuclear export, and pro-fibrotic cytokines. Selective JAK2 V617F inhibitors and targeting of mutant CALR by immunotherapy are the most intriguing and promising approaches. This review focuses on approved and experimental treatments for MF, highlighting their biological background.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Loscocco GG, Guglielmelli P. Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives. Am J Hematol. 2025. PMID: 40062529. doi:10.1002/ajh.27658

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。